December 29, 30, 2018, January 1, 2019 is a holiday, January 2, 2019 normal work.

FDA Approves Vaxelis FDA Approves Vaxelis Pediatric Hexavalent Combination Vaccine

FDA Approves Vaxelis FDA Approves Vaxelis Pediatric Hexavalent Combination Vaccine BRIDGEWATER, N.J. and KENILWORTH, N.J. – December 26, 2018 –The U.S. Food and Drug Administration has approved Vaxelis™ (Diphtheria and Tetanus Toxoids and Acellular Pe

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns Facebook Twitter Email to a friend Print this page

Horizon Pharma plc Announces FDA Approval to Expand the Age Range for Ravicti (glycerol phenylbutyrate) Oral Liquid to Include Newborns DUBLIN--(BUSINESS WIRE)--Dec. 27, 2018-- Horizon Pharma plc (NASDAQ: HZNP) today announced the U.S. Food and Drug Admi

Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer

Lynparza (olaparib) Approved by US FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer 19 December 2018 -- AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food an

FDA Approves Asparlas FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL)

FDA Approves Asparlas FDA Approves Asparlas (calaspargase pegol-mknl) for Acute Lymphoblastic Leukemia (ALL) On December 20, 2018, the Food and Drug Administration approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals LLC), an asparagine

FDA Approves Ultomiris FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

FDA Approves Ultomiris FDA Approves Ultomiris (ravulizumab-cwvz) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) BOSTON--(BUSINESS WIRE)-- December 21, 2018 -- Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Adminis